AHCOAdaptHealth Corp.
AdaptHealth Corp. (AHCO) operates in the healthcare-at-home sector, offering patient-centered solutions for home health and durable medical equipment (DME) services. The next catalyst is November 5, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to stabilize margins and deliver earnings above expectations amid ongoing cost pressures.
- Revenue in 2026 reached $3.04B, but net income remains negative at -$110.79M, with a net margin of -3.6% TTM.
- Free cash flow has improved to $137.44M TTM, though leverage remains at 1.16x debt-to-equity.
- Shareholders’ equity stands at $1.52B, with diluted EPS of -0.99, reflecting ongoing profitability challenges.
The Read
AHCO's annual centers and July 8 events historically trigger median absolute stock moves of about 11%.
The schedule
- Thu5Nov
The Q3 earnings release will test the company's financial performance against expectations, particularly in light of recent regulatory changes and operational challenges. The outcome will be critical for assessing the company's ability to manage costs and maintain margins.
- Tue12Jan
The conference will provide a platform for the company to showcase its strategy and progress, potentially influencing investor sentiment and short-term price action.
- Tue9Feb
The Q4 earnings release will provide further insight into the company's financial performance and operational efficiency, testing its ability to navigate regulatory and market challenges.
- Mon12Apr
The Q1 earnings release will provide critical insight into the company's financial performance and strategic execution, testing its ability to adapt to evolving market conditions.
- Wed4Aug
This event is tied to regulatory or compliance updates, which could influence investor sentiment and short-term price action.
- Thu5Aug
The Q2 earnings release will provide further insight into the company's financial performance and operational efficiency, testing its ability to navigate regulatory and market challenges.
Past
- Thu6Aug
Actual outcome: Bear · $5.80 at outcome
AdaptHealth beat EPS expectations but slashed full-year profitability guidance due to West Coast contract margin pressures and elevated costs. The stock collapsed below the bear floor amid ongoing securities fraud investigations, supplier price hikes, and a $106M revenue miss, reflecting heightened concerns over financial stability and legal risks.
Q2 2026 earnings release where ongoing margin pressures from the Kaiser contract transition and potential shareholder scrutiny could drive severe downside from the $10.16 base price.
- Wed8Jul
Actual outcome: Bull · $10.98 at outcome
The stock rallied 9.9% following the expected release of the annual CMS proposed rule for Home Health and DME Reimbursement. The positive price action indicates that the market viewed the updated reimbursement frameworks for DME and respiratory services as favorable or benign, removing regulatory overhang and driving shares toward the bull target.
Annual Centers for Medicare & Medicaid Services (CMS) proposed rule setting reimbursement frameworks for DME and respiratory services.
- Mon13Apr
Actual outcome: Bear · $10.72 at outcome
AdaptHealth met Q1 EPS expectations at -$0.74, but revealed higher-than-expected labor costs tied to a major capitated contract transition with Kaiser. These elevated costs dented EBITDA and pressured margins, driving the stock below the bear floor despite broad organic growth across its business lines.
Q1 2026 financial results, with particular focus on CPAP supply chain normalization and diabetes segment revenue.
- Tue24Feb
Actual outcome: Bull · $9.40 at outcome
AdaptHealth reported Q4 EPS of -$0.74, exactly matching consensus estimates. The stock rallied 6.1% following the release, as the in-line earnings results alleviated downside fears. Furthermore, management's subsequent presentation at the J.P. Morgan Global Leveraged Finance Conference provided reassuring visibility into the company's 2026 outlook and financial position, supporting the upward price action.
